000 03938nam a2200445 i 4500
999 _c6948
_d6948
001 6948
003 ES-MaUEC
005 20201203160822.0
006 a||||fo|||| 00| 0
007 cr nn nnnaamaa
008 200325s2020 gw | fo |||| 0|eng d
020 _a9783030388621
024 7 _a10.1007/978-3-030-38862-1
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRC268.3
_b.T86 2020 EB
245 0 0 _a Tumor Microenvironment
_cedited by Peter P. Lee, Francesco M. Marincola
250 _aFirst edition 2020
264 1 _aCham
_bSpringer International Publishing :
_bImprint: Springer
_c2020
300 _a1 recurso en línea (XXIV, 326 páginas)
_b61 ilustraciones, 56 ilustraciones a color
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _aArchivo de texto
_bPDF
490 0 _aCancer Treatment and Research
_x0927-3042
_v180
490 0 _aMedicine (Springer-11650)
505 0 _aPreface -- Part I: Imaging of tumor microenvironment, In vivo Imaging -- New technologies to image tumors -- Part II: Immune landscapes and their biology, Systemic correlates of the tumor microenvironment -- Adaptive immunity and the tumor microenvironment -- The biology of immune active cancers and their regulatory mechanisms -- The biology of immune excluded cancers -- Immunoscore -- Part III: The tumor microenvironment and therapy, The Immune Landscape in Women Cancers -- Translational biomarkers, combination therapies and their relationship with immune landscapes -- Effects of radiation on the tumor microenvironment -- Challenges of CAR T cell therapy for solid tumors.
520 3 _aThis book addresses the biological processes relevant to the immune phenotypes of cancer and their significance for immune responsiveness, based on the premise that malignant cells manipulate their surroundings through an evolutionary process that is controlled by interactions with innate immune sensors as well as the adaptive recognition of self/non-self. Checkpoint inhibitor therapy is now an accepted new form of cancer treatment. Other immuno-oncology approaches, such as adoptive cell therapy and metabolic inhibitors, have also shown promising results for specific indications. Immune resistance is common, however, limiting the efficacy of immunotherapy in many common cancer types. The reasons for such resistance are diverse and peculiar to the immune landscapes of individual cancers, and to the treatment modality used. Accordingly, approaches to circumvent resistance need to take into account context-specific genetic, biological and environmental factors that may affect the cancer immune cycle, and which can best be understood by studying the target tissue and correlated systemic immune markers. Understanding the major requirements for the evolutionary process governing human cancer growth in the immune-competent host will guide effective therapeutic choices that are tailored to the biology of individual cancers.
650 7 _2embne
_9207056
_aTumores
_xAspectos inmunológicos
650 7 _2embne
_9195595
_aCáncer
_xAspectos inmunológicos
700 1 _aLee, Peter P.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aMarincola, Francesco M.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_0http://id.loc.gov/authorities/names/n2005184151
710 2 _aSpringerLink (Online service)
_0http://id.loc.gov/authorities/names/no2005046756
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783030388614
776 0 8 _iPrinted edition:
_z9783030388638
776 0 8 _iPrinted edition:
_z9783030388645
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-38862-1
_zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
998 _db
_zSI